Belumosudil for chronic graft-versus-host disease after 2 or more prior lines of therapy: the ROCKstar Study

医学 不利影响 内科学 移植物抗宿主病 临床终点 胃肠病学 置信区间 移植 外科 随机对照试验
作者
Corey S. Cutler,Stephanie Joi Lee,Sally Arai,Marcello Rotta,Behyar Zoghi,Aleksandr Lazaryan,Aravind Ramakrishnan,Zachariah Michael DeFilipp,Amandeep Salhotra,Wanxing Chai‐Ho,Rohtesh S. Mehta,Trent Peng Wang,Mukta Arora,Iskra Pusic,Ayman A Saad,Nirav Niranjan Shah,Sunil Abhyankar,Carlos R. Bachier,John Patrick Galvin,Annie Im
出处
期刊:Blood [Elsevier BV]
卷期号:138 (22): 2278-2289 被引量:397
标识
DOI:10.1182/blood.2021012021
摘要

Belumosudil, an investigational oral selective inhibitor of Rho-associated coiled-coil-containing protein kinase 2 (ROCK2), reduces type 17 and follicular T helper cells via downregulation of STAT3 and enhances regulatory T cells via upregulation of STAT5. Belumosudil may effectively treat patients with chronic graft-versus-host disease (cGVHD), a major cause of morbidity and late nonrelapse mortality after an allogeneic hematopoietic cell transplant. This phase 2 randomized multicenter registration study evaluated belumosudil 200 mg daily (n = 66) and 200 mg twice daily (n = 66) in subjects with cGVHD who had received 2 to 5 prior lines of therapy. The primary end point was best overall response rate (ORR). Duration of response (DOR), changes in Lee Symptom Scale score, failure-free survival, corticosteroid dose reductions, and overall survival were also evaluated. Overall median follow-up was 14 months. The best ORR for belumosudil 200 mg daily and 200 mg twice daily was 74% (95% confidence interval [CI], 62-84) and 77% (95% CI, 65-87), respectively, with high response rates observed in all subgroups. All affected organs demonstrated complete responses. The median DOR was 54 weeks; 44% of subjects have remained on therapy for ≥1 year. Symptom reduction with belumosudil 200 mg daily and 200 mg twice daily was reported in 59% and 62% of subjects, respectively. Adverse events (AEs) were consistent with those expected in patients with cGVHD receiving corticosteroids and other immunosuppressants. Sixteen subjects (12%) discontinued belumosudil because of possible drug-related AEs. Belumosudil, a promising therapy for cGVHD, was well tolerated with clinically meaningful responses. This trial was registered at www.clinicaltrials.gov as #NCT03640481.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
刚刚
1秒前
Sissi发布了新的文献求助30
1秒前
1秒前
1秒前
王伟完成签到,获得积分10
2秒前
共享精神的应助被hailiangzheng采纳,获得10
2秒前
2秒前
2秒前
3秒前
李瑞程发布了新的文献求助10
3秒前
Rony发布了新的文献求助10
3秒前
4秒前
Ian发布了新的文献求助10
4秒前
酷酷的柚子完成签到,获得积分10
4秒前
九号球发布了新的文献求助10
5秒前
Czz发布了新的文献求助10
5秒前
5秒前
lmy的应助被zhang0403采纳,获得50
6秒前
aniannn完成签到,获得积分10
6秒前
fangxiang完成签到,获得积分10
6秒前
7秒前
大模型的应助被cxx采纳,获得10
7秒前
Mickey发布了新的文献求助10
7秒前
Lucas的应助被tang采纳,获得10
7秒前
CodeCraft的应助被平生采纳,获得50
8秒前
哭泣微笑发布了新的文献求助10
8秒前
8秒前
star完成签到,获得积分10
9秒前
健哥发布了新的文献求助10
9秒前
脑洞疼的应助被乎乎采纳,获得10
9秒前
9秒前
甜美战斗机完成签到,获得积分20
10秒前
Akashi完成签到,获得积分10
10秒前
风中孤晴完成签到 ,获得积分10
11秒前
12秒前
13秒前
HHH完成签到,获得积分20
13秒前
14秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
Improving the wear resistance of vehicle gear oil by oil soluble LaF3 nanoparticles and typical additives of gear oil 500
Boundaries and Bodhisattvas 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8183241
求助须知:如何正确求助?哪些是违规求助? 9572493
关于积分的说明 21826218
捐赠科研通 7780115
什么是DOI,文献DOI怎么找? 3433982
关于科研通互助平台的介绍 2558103
邀请新用户注册赠送积分活动 2480192